Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Madhavi Siddhanthi

Rheumatology Marietta, GA Medical Doctor

NPI 1659543130 CMS profile 120790

355 Tower Rd Ne Ste 103, Marietta, GA 30060

Open in the dashboard

General payments

$5,093

256 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madhavi Siddhanthi of Marietta, GA is reported in the CMS Open Payments database as having received $5,093 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,416 64
2024 General $1,477 74
2023 General $832 41
2022 General $485 28
2021 General $212 11
2020 General $253 14
2019 General $417 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madhavi Siddhanthi
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Madhavi Siddhanthi were reported at $1,416. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Madhavi Siddhanthi Rheumatology median Middle half National median
2019 $417 $744 $153–$2,687 $163
2020 $253 $462 $98–$2,027 $114
2021 $212 $531 $101–$2,153 $132
2022 $485 $627 $125–$2,303 $149
2023 $832 $741 $145–$2,524 $160
2024 $1,477 $830 $166–$2,660 $164
2025 $1,416 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,108 62 payments
  2. Janssen Biotech, Inc. $669 32 payments
  3. AbbVie, Inc. $497 26 payments
  4. Mallinckrodt Hospital Products Inc. $342 14 payments
  5. Novartis Pharmaceuticals Corporation $341 17 payments
  6. E.R. Squibb & Sons, L.L.C. $271 15 payments
  7. AstraZeneca Pharmaceuticals LP $257 12 payments
  8. Pfizer Inc. $251 15 payments
  9. Aurinia Pharma U.S., Inc. $231 9 payments
  10. UCB, Inc. $213 9 payments
  11. Other $914 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,934 252 payments
  2. Education $159 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $619 29 payments
  2. TAVNEOS $412 25 payments
  3. ACTHAR $342 14 payments
  4. Enbrel $295 15 payments
  5. ORENCIA $271 15 payments
  6. Otezla $260 14 payments
  7. SAPHNELO $257 12 payments
  8. COSENTYX $255 12 payments
  9. XELJANZ $235 14 payments
  10. LUPKYNIS $231 9 payments
  11. Other $2,318 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,532

Median for Rheumatology: 1,511

Drug cost

$453,935

Median for Rheumatology: $1,139,948

Branded share of claims

15.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 29 $241,273
Enbrel Sureclick Etanercept Brand 11 $91,345
Xeljanz Xr Tofacitinib Citrate Brand 12 $89,317
Hydroxychloroquine Sulfate Generic 226 $8,433
Methotrexate Methotrexate Sodium Brand 179 $3,506
Leflunomide Generic 58 $2,522
Pilocarpine Hcl Generic 22 $2,132
Febuxostat Generic 14 $2,042
Methylprednisolone Generic 98 $1,530
Mycophenolate Mofetil Generic 23 $1,488

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$98,358

Of which drugs: $45,391

Medicare patients

314

Average age 72

Services billed

3,725

235 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 32%
Osteoporosis 28%
Diabetes 21%
Depression 21%
Chronic kidney disease 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 24 2,160 $43,941
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 750 $70

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $184
$184 — —
TAVNEOS
  • Amgen Inc. $163
$163 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $158
$158 — —
Enbrel
  • Amgen Inc. $151
$151 11 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $149
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record